Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Michiels

Showing results (321-330 of 345) with videos related to

Pageof 35
Sort By:
Journal of Animal Science|November 30, 2016
Vitamin E plasma kinetics in swine show low bioavailability and short half-life of -α-tocopheryl acetateT A T G van Kempen, M H Reijersen, C de Bruijn, et al.
American Journal of Human Genetics|April 3, 2001
The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32J P Drenth, W H Finley, G J Breedveld, et al.
Thrombosis and Haemostasis|September 1, 1996
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generationP J van Genderen, I S Lucas, R van Strik, et al.
Thrombosis Research|December 18, 2003
Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantationMarc G Van der Planken, Marc J Claeys, Francine J Vertessen, et al.
International Angiology : a Journal of the International Union of Angiology|January 24, 2014
Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient wardJ J Michiels, W Moosdorff, H Maasland, et al.
European Cells & Materials|January 12, 2017
Controlled release of chlorhexidine from a mesoporous silica-containing macroporous titanium dental implant prevents microbial biofilm formationK De Cremer, A Braem, E Gerits, et al.
British Journal of Haematology|January 31, 1998
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet countP J van Genderen, F J Prins, I S Lucas, et al.
Thrombosis and Haemostasis|April 22, 1985
Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch familiesA W Broekmans, R M Bertina, J Reinalda-Poot, et al.
Journal of Pediatric Hematology/Oncology|April 7, 2009
A novel type 2A von Willebrand factor mutation (V1499E) associated with variable clinical expressionEsther van den Heuvel, Bas de Laat, Carel M Eckmann, et al.
Seminars in Hematology|April 1, 1994
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study GroupP Sonneveld, W Hop, A H Mulder, et al.
Pageof 35

Showing results (321-330 of 345) with videos related to

Sort By:
Pageof 35
Journal of Animal Science|November 30, 2016
Vitamin E plasma kinetics in swine show low bioavailability and short half-life of -α-tocopheryl acetateT A T G van Kempen, M H Reijersen, C de Bruijn, et al.
American Journal of Human Genetics|April 3, 2001
The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32J P Drenth, W H Finley, G J Breedveld, et al.
Thrombosis and Haemostasis|September 1, 1996
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generationP J van Genderen, I S Lucas, R van Strik, et al.
Thrombosis Research|December 18, 2003
Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantationMarc G Van der Planken, Marc J Claeys, Francine J Vertessen, et al.
International Angiology : a Journal of the International Union of Angiology|January 24, 2014
Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient wardJ J Michiels, W Moosdorff, H Maasland, et al.
European Cells & Materials|January 12, 2017
Controlled release of chlorhexidine from a mesoporous silica-containing macroporous titanium dental implant prevents microbial biofilm formationK De Cremer, A Braem, E Gerits, et al.
British Journal of Haematology|January 31, 1998
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet countP J van Genderen, F J Prins, I S Lucas, et al.
Thrombosis and Haemostasis|April 22, 1985
Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch familiesA W Broekmans, R M Bertina, J Reinalda-Poot, et al.
Journal of Pediatric Hematology/Oncology|April 7, 2009
A novel type 2A von Willebrand factor mutation (V1499E) associated with variable clinical expressionEsther van den Heuvel, Bas de Laat, Carel M Eckmann, et al.
Seminars in Hematology|April 1, 1994
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study GroupP Sonneveld, W Hop, A H Mulder, et al.
Pageof 35